Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Replication factor C subunit 1 (RFC1) is the large (140 kDa) subunit of the replication factor C complex, a heteropentameric protein essential for eukaryotic DNA replication and repair[3][5][2]. As a DNA-dependent ATPase, RFC1 cooperates with DNA polymerases and loads proliferating cell nuclear antigen (PCNA) onto DNA, facilitating the formation of a sliding clamp required for high-fidelity DNA synthesis[1][2][7][5]. This protein also binds both single- and double-stranded DNA, promotes elongation of DNA strands during replication, and functions in telomere maintenance, mismatch repair, base excision repair, and cell cycle checkpoint signaling[1][5][7]. RFC1 genetic mutations, particularly biallelic pentanucleotide repeat expansions (notably “AAGGG”) in an intronic Alu element, are a recognized cause of cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) and related neurological phenotypes[3][1]. RFC1 function is vital for genome stability, but current evidence does not indicate it as a direct therapeutic target for small molecules or drugs, and it is not associated with increased cancer risk in affected individuals with repeat expansions[1]. RFC1 may influence transcriptional programs through protein–protein interactions (e.g., with NF-κB/RelA, HDAC1)[2]; however, its core cellular functionality is as a DNA clamp loader in conjunction with the PCNA sliding clamp, serving as an accessory factor for DNA polymerases. Note: RFC1 is not considered a therapeutic target such as a receptor, enzyme, or transporter suitable for direct pharmacological modulation. It is, however, a critical gene important for DNA replication and repair and is best recognized as a biomarker in neurogenetic diagnosis rather than as a drug target[1][3][5][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Replication factor C subunit 1 (RFC1).